

## Accurate, objective, automated results you can rely on.

Accurate: Excellent sensitivity and specificity compared to molecular and viral culture methods.

**Objective:** Fluorescent technology guarantees an objective result with no potential for subjective

interpretation.

Easy: Simple workflows with as few as one button press and ~1 minute of hands-on time.

**Fast:** Results in 3-15 minutes (differs by assay).

Convenient: Small instrument size and room-temp storage of kits are suitable for any office or lab.

**Efficient:** Automatically stores patient results – results never expire! View results from your

computer using Virena.





**WALK AWAY** mode lets the Test Cassette incubate inside Sofia 2 and reports a result automatically upon completion.

**READ NOW** mode lets you incubate multiple Test Cassettes on the bench top and quickly analyze them one by one in Sofia 2.

Choice without compromise.















Lyme FIA

Campylobacter FIA

Flu + SARS FIA\*

Influenza A+B FIA

SARS Antigen FIA\*

RSV FIA

Strep A+ FIA

Touchscreen display and graphical user interface

Integrated barcode scanner to capture user and patient information.

Optional external printer.

Export results and data to external media.

LIS integration capability via ethernet.

2 USB ports.






## **Analytics enhancing diagnostics**

Virena provides the platform to communicate the early detection of disease onset and its progression within your community. With Virena, you can observe, track, report and respond rapidly to emerging infectious diseases trending in your area, improving community awareness and infectious disease prevention — ultimately leading to a healthier community.

## What's going around?

Whether it's disease mapping to determine local prevalence and disease trends, automating and aggregating decentralized quality control, readjusting personnel or inventory based on real-time demands, or cross checking test volumes vs. billing, Virena provides the analytics to help you make the best use of your point-of-care investment.



\*THESE TESTS ARE AVAILABLE FOR SALE IN THE USA UNDER EMERGENCY USE AUTHORIZATION. These SARS tests have not been FDA cleared or approved, but have been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless terminated or revoked sooner.